Toronto Dominion Bank Decreases Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Toronto Dominion Bank decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 21.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 33,405 shares of the company's stock after selling 8,878 shares during the period. Toronto Dominion Bank's holdings in IDEXX Laboratories were worth $13,811,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Hantz Financial Services Inc. increased its stake in IDEXX Laboratories by 11.5% in the 4th quarter. Hantz Financial Services Inc. now owns 7,738 shares of the company's stock valued at $3,199,000 after buying an additional 800 shares during the last quarter. Paragon Capital Management Inc. increased its stake in IDEXX Laboratories by 25.7% in the 4th quarter. Paragon Capital Management Inc. now owns 3,820 shares of the company's stock valued at $1,579,000 after buying an additional 782 shares during the last quarter. Manitou Investment Management Ltd. increased its stake in IDEXX Laboratories by 491.0% in the 4th quarter. Manitou Investment Management Ltd. now owns 52,202 shares of the company's stock valued at $21,582,000 after buying an additional 43,369 shares during the last quarter. Fiera Capital Corp increased its stake in IDEXX Laboratories by 12.3% in the 4th quarter. Fiera Capital Corp now owns 141,198 shares of the company's stock valued at $58,377,000 after buying an additional 15,463 shares during the last quarter. Finally, Lecap Asset Management Ltd. increased its stake in IDEXX Laboratories by 587.7% in the 4th quarter. Lecap Asset Management Ltd. now owns 5,701 shares of the company's stock valued at $2,357,000 after buying an additional 4,872 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Stock Up 0.7%

IDXX opened at $521.68 on Tuesday. The company has a 50 day moving average of $433.47 and a 200 day moving average of $432.18. The company has a market cap of $41.95 billion, a PE ratio of 48.89, a price-to-earnings-growth ratio of 3.41 and a beta of 1.52. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $545.43. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The company had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. During the same period last year, the firm earned $2.71 EPS. IDEXX Laboratories's revenue for the quarter was up 3.6% on a year-over-year basis. On average, sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on IDXX. StockNews.com upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Friday, May 9th. Morgan Stanley raised their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research note on Monday, May 5th. Barclays raised their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. Stifel Nicolaus raised their price target on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research note on Monday. Finally, Bank of America raised their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 4th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $536.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.